지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 25 - 45 (21page)
이용수
초록· 키워드
오류제보하기
Recently introduced PLS (positive list system) policy in Korea intends to gain cost effective in drug expenditure, by allowing reasonable prices relative to products' effectiveness. Under the increasingly constrained health budget situation, it is a reasonable policy tool to be used in any country. However, it does not allow one, as contrary to one easily hopes, to control total drug expenditure. In terms of health policy tools for drug expenditure management, if controlling drug expenditure were set as an objective of health policy in one's setting, one may need additional tools. One such tool Korea can think of under the current situation of rapidly rising drug expenditure is the fixed budget for pharmaceuticals.
It would be rather a stringent policy tool from the pharmaceutical industry's point of view, but if one extends the perspective to society level, it can be considered as a reasonable option. In particular, as in Korea where pharmaceutical policy has been mostly in the form of price control, management of drug expenditure can now be extended toward quantity control as well. Fixed drug budget(FDB), in that regard, is an option open to Korea now. If FDB is considered as a possible policy option, a carefully designed impact analysis from all different angles is strongly encouraged. This is because the same policy could have different kinds and level of impacts under different health care systems. No matter what, it is about time for Korea to consider FDB as a drug policy option.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
이 논문의 저자 정보
최근 본 자료
댓글(0)
0